We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2326
Peoples Financial Services
PFIS
$716M
| $543K | ﹤0.01% |
10,785
-39
| -0.4% | -$1.91K |
|
2327
AnaptysBio
ANAB
$1.63B
| $541K | ﹤0.01% |
33,303
+288
| +0.9% | +$6.81K |
|
2328
Caesarstone
CSTE
$80.2M
| $539K | ﹤0.01% |
35,745
+278
| +0.8% | +$4.46K |
|
2329
Twist Bioscience
TWST
$7.16B
| $539K | ﹤0.01% |
25,653
+628
| +3% | +$14.7K |
|
2330
Citizens
CIA
$235M
| $536K | ﹤0.01% |
79,389
+668
| +0.8% | +$4.6K |
|
|
SEI
2331
Solaris Energy Infrastructure
SEI
$3.41B
| $536K | ﹤0.01% |
38,292
+680
| +2% | +$8.18K |
|
|
NETI
2332
DELISTED
Eneti Inc.
NETI
| $536K | ﹤0.01% |
8,416
-539
| -6% | -$32.8K |
|
2333
Digimarc Corp
DMRC
$167M
| $534K | ﹤0.01% |
15,917
+72
| +0.5% | +$2.58K |
|
|
AD
2334
Array Digital Infrastructure
AD
$3.04B
| $533K | ﹤0.01% |
14,719
+1,676
| +13% | +$58.7K |
|
|
CHNG
2335
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $531K | ﹤0.01% |
32,403
+5,577
| +21% | +$74.8K |
|
|
REVG
2336
DELISTED
REV Group
REVG
| $530K | ﹤0.01% |
43,351
+420
| +1% | +$5.31K |
|
|
NPTN
2337
DELISTED
NEOPHOTONICS CORP
NPTN
| $529K | ﹤0.01% |
59,968
+771
| +1% | +$5.77K |
|
2338
GrafTech
EAF
$200M
| $522K | ﹤0.01% |
4,495
+24
| +0.5% | +$3.02K |
|
2339
Daily Journal
DJCO
$825M
| $520K | ﹤0.01% |
1,789
+1
| +0.1% | +$280 |
|
|
WAAS
2340
DELISTED
AquaVenture Holdings Limited
WAAS
| $520K | ﹤0.01% |
19,182
+858
| +5% | +$18.2K |
|
2341
CytomX Therapeutics
CTMX
$729M
| $518K | ﹤0.01% |
62,355
+1,147
| +2% | +$7.74K |
|
2342
1-800-Flowers.com
FLWS
$265M
| $518K | ﹤0.01% |
35,754
+221
| +0.6% | +$3K |
|
|
PCSB
2343
DELISTED
PCSB Financial Corporation
PCSB
| $518K | ﹤0.01% |
25,575
+82
| +0.3% | +$1.66K |
|
|
MNK
2344
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $518K | ﹤0.01% |
148,381
+8,526
| +6% | +$26.6K |
|
2345
Calix
CALX
$2.42B
| $516K | ﹤0.01% |
64,507
+336
| +0.5% | +$2.5K |
|
|
PRMW
2346
DELISTED
Primo Water Corporation
PRMW
| $515K | ﹤0.01% |
45,874
+319
| +0.7% | +$3.54K |
|
2347
Utah Medical Products
UTMD
$227M
| $514K | ﹤0.01% |
4,768
+35
| +0.7% | +$3.55K |
|
2348
VSE Corp
VSEC
$6.05B
| $514K | ﹤0.01% |
13,503
+147
| +1% | +$5.47K |
|
|
LTS
2349
DELISTED
Ladenburg Thalmann Financial Services Inc
LTS
| $512K | ﹤0.01% |
147,038
+2,027
| +1% | +$5.88K |
|
2350
Clean Energy Fuels
CLNE
$414M
| $510K | ﹤0.01% |
218,056
+1,634
| +0.8% | +$3.47K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.